Found 2 results
Filters: Author is E. Alp [Clear All Filters]
“Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells”, vol. 12, pp. 5405-5413, 2013.,
“The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats”, vol. 10, pp. 2962-2975, 2011.,
Alberti KG and Zimmet PZ (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553. Alcendor RR, Gao S, Zhai P, Zablocki D, et al. (2007). Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100: 1512-1521. Andlauer W, Kolb J, Siebert K and Furst P (2000). Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res. 26: 47-55. Asou H, Koshizuka K, Kyo T, Takata N, et al. (2002). Resveratrol, a natural product derived from grapes, is a new inducer of differentiation in human myeloid leukemias. Int. J. Hematol. 75: 528-533. Ates O, Cayli S, Yucel N and Altinoz E (2007). Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J. Clin. Neurosci. 14: 256-260. Banerjee S, Bueso-Ramos C and Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62: 4945-4954. Bertelli AA, Giovannini L, Stradi R, Urien S, et al. (1998). Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp. Clin. Res. 24: 51-55. Borra MT, Smith BC and Denu JM (2005). Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280: 17187-17195. Dubois RN, Abramson SB, Crofford L, Gupta RA, et al. (1998). Cyclooxygenase in biology and disease. FASEB J. 12: 1063-1073. Fremont L (2000). Biological effects of resveratrol. Life Sci. 66: 663-673. Gao Z and Ye J (2008). Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun. 376: 793-796. Holmes-McNary M and Baldwin AS Jr (2000). Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60: 3477-3483. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196. Jang M, Cai L, Udeani GO, Slowing KV, et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220. Jiang WJ (2008). Sirtuins: novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun. 373: 341-344. Juan ME, Vinardell MP and Planas JM (2002). The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132: 257-260. Karin M (1999). How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18: 6867-6874. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, et al. (2005). Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am. J. Physiol. Renal Physiol. 288: F1053-F1068. Kumar A, Kaundal RK, Iyer S and Sharma SS (2007). Effects of resveratrol on nevre functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 80: 1236-1244. Kundu JK and Surh YJ (2004). Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat. Res. 555: 65-80. Lee JH, Song MY, Song EK, Kim EK, et al. (2009). Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 58: 344-351. Manna SK, Mukhopadhyay A and Aggarwal BB (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164: 6509-6519. Martinez J and Moreno JJ (2000). Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59: 865-870. Milne JC, Lambert PD, Schenk S, Carney DP, et al. (2007). Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716. Nemoto S, Fergusson MM and Finkel T (2004). Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105-2108. Pervaiz S (2003). Resveratrol: from grapevines to mammalian biology. FASEB J. 17: 1975-1985. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, et al. (2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. U. S. A. 105: 9793-9798. Philip S, Bulbule A and Kundu GC (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276: 44926-44935. Pillarisetti S (2008). A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat. Cardiovasc. Drug Discov. 3: 156-164. Robertson RP and Harmon JS (2006). Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic. Biol. Med. 41: 177-184. Rodgers JT, Lerin C, Haas W, Gygi SP, et al. (2005). Nutrient control of glucose homeostasis through a complex of PGC- 1alpha and SIRT1. Nature 434: 113-118. Sharma S, Anjaneyulu M, Kulkarni SK and Chopra K (2006). Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76: 69-75. Smith WL, DeWitt DL and Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69: 145-182. St-Pierre Y, Couillard J and Van Themsche C (2004). Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin. Ther. Targets 8: 473-489. Stumvoll M, Goldstein BJ and van Haeften TW (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346. Su HC, Hung LM and Chen JK (2006). Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 290: E1339-E1346. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, et al. (1998). Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273: 21875-21882. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, et al. (2010). Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 298: 833-843. Surh YJ, Chun KS, Cha HH, Han SS, et al. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480-481: 243-268. Szewczuk LM, Forti L, Stivala LA and Penning TM (2004). Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279: 22727-22737. Tanno M, Kuno A, Yano T, Miura T, et al. (2010). Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 285: 8375-8382. Tsai SH, Lin-Shiau SY and Lin JK (1999). Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126: 673-680. Woo JH, Lim JH, Kim YH, Suh SI, et al. (2004). Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23: 1845-1853. Wood JG, Rogina B, Lavu S, Howitz K, et al. (2004). Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689. Yar AS, Menevse S, Alp E, Helvacioglu F, et al. (2010). The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol. Biol. Rep. 37: 2323-2331. Yu C, Shin YG, Chow A, Li Y, et al. (2002). Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19: 1907- 1914. Yu H, Pan C, Zhao S, Wang Z, et al. (2008). Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother. 62: 366-372.